The diverse functions of the PD1 inhibitory pathway (Q47678849)

4 February 2018

title

The diverse functions of the PD1 inhibitory pathway (English)

1 reference

4 February 2018

author name string

Arlene H Sharpe

series ordinal

1 reference

4 February 2018

Kristen E Pauken

series ordinal

1 reference

4 February 2018

publication date

9 October 2017

1 reference

4 February 2018

Nature Reviews Immunology

published in

1 reference

4 February 2018

cites work

The B7 family revisited

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

PD-1 signaling in primary T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Overcoming T cell exhaustion in infection and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Restoring function in exhausted CD8 T cells during chronic viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Immune modulation in cancer with antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Immune checkpoint blockade: a common denominator approach to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy human adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Combinatorial Cancer Immunotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

The future of immune checkpoint therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Elements of cancer immunity and the cancer-immune set point

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Molecular and transcriptional basis of CD4⁺ T cell dysfunction during chronic infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8(+) Cytolytic T Cell Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

The epigenetic landscape of T cell exhaustion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4(+) T cells tolerized by peptide immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Posttranscriptional control of T cell effector function by aerobic glycolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Targeting T cell metabolism for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

What does PD-L1 positive or negative mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Antigen-independent memory CD8 T cells do not develop during chronic viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Persistence of memory CD8 T cells in MHC class I-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Functional responses and costimulator dependence of memory CD4+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Multiple layers of CD80/86-dependent costimulatory activity regulate primary, memory, and secondary lymphocytic choriomeningitis virus-specific T cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Limiting the Amount and Duration of Antigen Exposure during Priming Increases Memory T Cell Requirement for Costimulation during Recall

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Programmed Death 1 Regulates Development of Central Memory CD8 T Cells after Acute Viral Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Recall responses by helpless memory CD8+ T cells are restricted by the up-regulation of PD-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

The PD-1/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungus Histoplasma capsulatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Target-dependent B7-H1 regulation contributes to clearance of central nervous system infection and dampens morbidity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

PD-1 on dendritic cells impedes innate immunity against bacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Viral acute lower respiratory infections impair CD8+ T cells through PD-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

PDL-1 blockade impedes T cell expansion and protective immunity primed by attenuated Listeria monocytogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

B7-H1 (PD-L1) on T cells is required for T-cell-mediated conditioning of dendritic cell maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

T follicular regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Transcriptional control of effector and memory CD8+ T cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Disparate individual fates compose robust CD8+ T cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Heterogeneous differentiation patterns of individual CD8+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Facilitation of beta selection and modification of positive selection in the thymus of PD-1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

PD-1, but not PD-L1, expressed by islet-reactive CD4+ T cells suppresses infiltration of the pancreas during type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Cutting edge: identification of autoreactive CD4+ and CD8+ T cell subsets resistant to PD-1 pathway blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Tissue expression of PD-L1 mediates peripheral T cell tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Dynamic Changes in Chromatin Accessibility Occur in CD8+ T Cells Responding to Viral Infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Exhaustion-associated regulatory regions in CD8+ tumor-infiltrating T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Delivering PD-1 inhibitory signal concomitant with blocking ICOS co-stimulation suppresses lupus-like syndrome in autoimmune BXSB mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Enhancing SIV-specific immunity in vivo by PD-1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Follicular CXCR5- expressing CD8(+) T cells curtail chronic viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Cutting edge: gut microenvironment promotes differentiation of a unique memory CD8 T cell population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Antigen-independent differentiation and maintenance of effector-like resident memory T cells in tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

The integration of T cell migration, differentiation and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Systemic Immunity Is Required for Effective Cancer Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Accessories to the crime: functions of cells recruited to the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

PD-1 blockade induces responses by inhibiting adaptive immune resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

21 January 2018

Cancer genome landscapes

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Genetic basis for clinical response to CTLA-4 blockade in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Interferons and the Immunogenic Effects of Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Blockade of chronic type I interferon signaling to control persistent LCMV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Persistent LCMV infection is controlled by blockade of type I interferon signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

A critical role for the programmed death ligand 1 in fetomaternal tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

B7 family molecules are favorably positioned at the human maternal-fetal interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Single-cell RNA-seq identifies a PD-1hi ILC progenitor and defines its development pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

IL-27 renders DC immunosuppressive by induction of B7-H1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Molecular biology, genetics and biochemistry of the repulsive guidance molecule family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

RGMs: Structural Insights, Molecular Regulation, and Downstream Signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Mechanisms of PDL1-mediated regulation of autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Endothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8+ T cell activation and cytolysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

T cell clones to epitopes of glutamic acid decarboxylase 65 raised from normal subjects and patients with insulin-dependent diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Minor myelin proteins can be major targets for peripheral blood T cells from both multiple sclerosis patients and healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

A link between PDL1 and T regulatory cells in fetomaternal tolerance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.108

Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells

31 March 2020

1 reference

12 December 2020

B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma

1 reference

12 December 2020

Role of CD28-B7 interactions in generation and maintenance of CD8 T cell memory

1 reference

12 December 2020

Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity

1 reference

12 December 2020

Induction and visualization of mucosal memory CD8 T cells following systemic virus infection

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRI.2017.108

1 reference

4 February 2018

1 reference

4 February 2018